Latest cyclophosphamide Stories
-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV MELBOURNE, Australia and LUGANO, Switzerland, May 8, 2015 /PRNewswire/ -- Australian biopharmaceutical company
Newly published research finds that a combination of oral drugs may offer an additional treatment option for mesothelioma patients who have already undergone chemotherapy. Raleigh,
-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV -- LUGANO, Switzerland and WOODCLIFF LAKE, N.J., Oct. 13, 2014 /PRNewswire/ -- Helsinn Group and Eisai Inc.
Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer.
Scientists from Northwestern Medicine have brought new hope to patients with Lupus. A new nontoxic therapy that suppresses Lupus in blood samples was designed and successfully tested on patients with the autoimmune disease.
In an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxan, Genentech, Inc.) is as effective as the current standard of care regimen of drugs for remission induction and maintenance in patients with ANCA-associated Vasculitis (AAV).
According to new research there is a strong connection between higher rates of relapse in pediatric cancer patients and drug substitutions due to shortages.
- A woman chauffeur.
- A woman who operates an automobile.